AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
10.97
+0.61 (5.89%)
At close: Aug 13, 2026, 4:00 PM EDT
10.96
-0.01 (-0.09%)
After-hours: Aug 13, 2026, 7:59 PM EDT
AbCellera Biologics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, AbCellera Biologics stock has a consensus rating of "Strong Buy" and an average price target of $17.13. The average 1-year stock price forecast is 56.15% higher than the current stock price, while the lowest is $9.00 (-17.96%) and the highest is $30 (+173.47%).
Price Target: $17.13 (+56.15%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for AbCellera Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 7 | 8 | 8 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Buy Maintains $7 → $15 | Buy | Maintains | $7 → $15 | +36.74% | Aug 11, 2026 |
| JonesTrading | JonesTrading | Buy Reiterates $13 → $25 | Buy | Reiterates | $13 → $25 | +127.89% | Aug 10, 2026 |
| Truist Financial | Truist Financial | Buy Reiterates $12 → $30 | Buy | Reiterates | $12 → $30 | +173.47% | Aug 10, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $12 | Buy | Maintains | $12 | +9.39% | Aug 7, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $11 → $12 | Buy | Reiterates | $11 → $12 | +9.39% | Aug 6, 2026 |
Financial Forecast
Revenue This Year
25.43M
from 75.13M
Decreased by -66.16%
Revenue Next Year
25.34M
from 25.43M
Decreased by -0.33%
EPS This Year
-0.66
from -0.49
EPS Next Year
-0.71
from -0.66
EPS and Forward PE are based on non-GAAP adjusted numbers.